Welcome to our dedicated page for Can-Fite BioPharma Ltd. news (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma Ltd. stock.
Can-Fite BioPharma Ltd. (CANF) is a clinical-stage biopharmaceutical innovator advancing oral therapies for cancer, liver diseases, and inflammatory conditions through its proprietary A3 adenosine receptor (A3AR) platform. This page serves as your definitive source for official company announcements, clinical trial updates, and strategic developments.
Investors and industry professionals will find curated press releases detailing progress across Can-Fite’s pipeline, including Phase II/III trials for Piclidenoson in psoriasis and Namodenoson’s dual applications in liver cancer and NASH. All content is verified through primary sources to ensure accuracy and timeliness.
Key updates cover regulatory milestones, partnership announcements, and peer-reviewed research findings. The collection emphasizes developments in targeted small molecule therapeutics while maintaining accessibility for both specialist and general audiences.
Bookmark this page to efficiently monitor Can-Fite’s advancements in addressing multi-billion dollar medical markets through its differentiated A3AR approach. Check regularly for critical updates that may influence market positioning and therapeutic innovation.
Can-Fite BioPharma (NYSE American: CANF) is advancing a topical treatment for psoriasis using its Phase III oral drug candidate, Piclidenoson. Recent preclinical studies show significant efficacy in managing psoriasis symptoms. The global psoriasis drug market, valued at $11.37 billion, is projected to grow at a CAGR of 6.5%. Can-Fite expects to release topline results for its Phase III trial in Q2 2022, with positive interim data supporting the development of its topical formulation as a complement to the oral treatment.
Can-Fite BioPharma Ltd (NYSE American: CANF) announced that CEO Dr. Pnina Fishman will present at the 3rd Annual Dermatology Drug Development Summit on April 6, 2022, showcasing the lead drug candidate Piclidenoson for psoriasis treatment. Enrollment in the Phase III Comfort™ study is complete with 400 patients across 30 sites in Europe, Israel, and Canada, with topline data expected in Q2 2022. The company has received approximately $20 million from licensing agreements, enhancing its market reach in various countries.
Can-Fite BioPharma (NYSE: CANF) announced its financial results for the year ended December 31, 2021, reporting revenues of $0.85 million, up from $0.76 million in 2020. The company had a cash balance of $18.9 million at year-end. Key developments include a significant $42.7 million out-licensing deal with Ewopharma and positive Phase II results for Namodenoson in liver cancer. A Phase III study for liver cancer is set to start in H1 2022, and topline data for psoriasis is expected in Q2 2022.
Can-Fite BioPharma Ltd (NYSE: CANF) announced a Notice of Allowance from the U.S. Patent and Trademark Office for its method to treat advanced liver fibrosis with Namodenoson. This expansion targets various liver conditions including NASH and liver cancer, tapping into a market projected to exceed $20 billion by 2020.
The company is currently enrolling patients for a Phase IIb trial for NASH and plans to begin a Phase III trial for advanced liver cancer. Namodenoson boasts a strong safety profile and significant commercial potential.
Can-Fite BioPharma Ltd (NYSE American: CANF) announced its CEO, Dr. Pnina Fishman, will present research at the CannX Medical Cannabis Conference on March 14-15, 2022, focusing on cannabinoids' role in liver cancer treatment.
Key findings indicate that CBD-rich T3/C15 can inhibit hepatocellular carcinoma growth at low concentrations by activating the A3 adenosine receptor. Can-Fite is exploring collaboration opportunities within the cannabis sector for potential licensing.
The abstract will be published in the Medical Cannabis and Cannabinoids journal.
Can-Fite BioPharma (NYSE American: CANF) announced an unexpected delay in releasing top-line data from its Phase III Comfort™ study of Piclidenoson for treating plaque psoriasis, now expected in Q2 2022. The study involves over 400 patients across Europe, Israel, and Canada. Piclidenoson aims to target key cytokines involved in skin lesions. The psoriasis market is projected to reach $11.3 billion by 2025, with potential milestone payments from out-licensing agreements. The company remains optimistic about the drug's effectiveness with minimal side effects.
Can-Fite BioPharma (NYSE American: CANF) announced the enrollment of the first patient in a Phase IIb study for its drug candidate Namodenoson, targeting non-alcoholic steatohepatitis (NASH). This multicenter, randomized trial aims to assess Namodenoson's efficacy compared to placebo in 140 subjects over 36 weeks. The NASH market is projected to reach $35-$40 billion by 2025, highlighting the growth potential. Previous Phase IIa results indicated promising outcomes related to liver fibrosis and inflammation.
Can-Fite BioPharma (NYSE American: CANF) has out-licensed its psoriasis drug, Piclidenoson, in major markets including Canada, Europe, and Asia. Recent pre-clinical studies show that Piclidenoson effectively destroys pathological skin cells, supporting its potential in treating psoriasis. The ongoing Phase III trial in Europe and Canada aims to demonstrate efficacy via PASI score improvements. The psoriasis market is projected to reach $11.3 billion by 2025, which could enhance Can-Fite's market position with milestone payments and royalties expected upon regulatory approval.
Can-Fite BioPharma (NYSE American: CANF) announced plans to hold virtual investor meetings at the J.P. Morgan Healthcare Conference. The company reported a complete response to Namodenoson for hepatocellular carcinoma (HCC) in its Phase II study. In Q1 2022, patient enrollment for a pivotal Phase III trial for HCC is expected to commence, supported by the FDA and EMA’s approval of the study design. Namodenoson has Orphan Drug Designation in the U.S. and Europe, with Fast Track Status in the U.S.
These developments position Can-Fite favorably in the competitive biopharma landscape.
Can-Fite BioPharma Ltd (NYSE American: CANF) announced key upcoming events expected to enhance shareholder value throughout 2022. The company plans to release topline data from a Phase III psoriasis study in Q1 2022, examining a primary endpoint related to Piclidenoson. Additionally, it will commence enrollment in a Phase IIb NASH study and a Phase III liver cancer study in H1 2022. Can-Fite has raised $10 million recently, complementing $13.3 million reported in Q3 2021, positioning the company well for ongoing clinical trials.
FAQ
What is the current stock price of Can-Fite BioPharma Ltd. (CANF)?
What is the market cap of Can-Fite BioPharma Ltd. (CANF)?
